Vaccinex, Inc. (VCNX)
Stock Price:
$3.33 USD
-0.14 (-4.03%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
55.43M |
| Revenue (ttm) |
429,000 |
| Net Income (ttm) |
-29.95M |
| Shares Out |
16.36M |
| EPS (ttm) |
-2.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$3.33 |
| Previous Close |
$3.47 |
| Change ($) |
-0.14 |
| Change (%) |
-4.03% |
| Day's Open |
3.42 |
| Day's Range |
3.27 - 3.50 |
| Day's Volume |
46,759 |
| 52-Week Range |
3.22 - 12.23 |
More Stats
| Market Cap |
55.43M |
| Enterprise Value |
52.94M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.36M |
| Float |
3.74M |
| EPS (basic) |
-2.16 |
| EPS (diluted) |
-2.14 |
| FCF / Share |
-1.88 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
197,854 |
| Short Ratio |
4.58 |
| Short % of Float |
2.99% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
129.20 |
| PB Ratio |
n/a |
| Revenue |
429,000 |
| Operating Income |
-30.03M |
| Net Income |
-29.95M |
| Free Cash Flow |
-30.08M |
| Net Cash |
2.49M |
| Net Cash / Share |
0.15 |
| Gross Margin |
75.52% |
| Operating Margin |
-7,000.93% |
| Profit Margin |
-6,980.20% |
| FCF Margin |
-7,011.89% |
| ROA |
-206.56% |
| ROE |
-1,303.09% |
| ROIC |
554.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.33*
(540.54% upside)
Low
20.0
Current: 3.33
High
22.0
Target: 21.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 0.52 | 0.72 | 0.09 | 0.32 |
| Revenue Growth | -27.76% | 704.44% | -71.52% | - |
| Gross Profit | 0.32 | -0.31 | -0.07 | 0.20 |
| Operating Income | -32.02 | -27.28 | -21.10 | -20.26 |
| Net Income | -31.86 | -29.52 | -18.72 | -13.94 |
| Shares Outstanding | 12.88 | 5.22 | 1.10 | 1.04 |
| Earnings Per Share | -2.47 | -5.65 | -19.90 | -25.27 |
| Operating Cash Flow | -30.72 | -25.28 | -21.39 | -19.72 |
| Capital Expenditures | -0.08 | -0.24 | -0.07 | -0.79 |
| Free Cash Flow | -30.79 | -25.51 | -21.46 | -20.51 |
| Cash & Equivalents | 2.78 | 19.72 | 4.18 | 1.66 |
| Total Debt | - | - | 2.81 | 1.04 |
| Net Cash / Debt | 2.78 | 19.72 | 1.37 | 0.62 |
| Assets | 4.60 | 22.03 | 5.58 | 2.84 |
| Liabilities | 6.88 | 6.69 | 7.35 | 6.17 |
| Book Value | -26.24 | -8.62 | -125 | -107 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Vaccinex, Inc. |
| Country |
United States |
| Employees |
45 |
| CEO |
Maurice Zauderer |
Stock Information
| Ticker Symbol |
VCNX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VCNX |
Description
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.